XML 36 R28.htm IDEA: XBRL DOCUMENT v3.24.3
Net Loss per Share (Tables)
9 Months Ended
Sep. 30, 2024
Earnings Per Share [Abstract]  
Schedule of Computation of Basic and Diluted Net Loss per Share

The following table sets forth the computation of the Company's basic and diluted net loss per share:

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(32,725

)

 

$

(20,980

)

 

$

(82,100

)

 

$

(75,679

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Shares used to compute net loss per share, basic and
   diluted

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares of common stock
   outstanding

 

 

38,730,839

 

 

 

20,059,641

 

 

 

37,568,821

 

 

 

19,767,174

 

Weighted average shares of pre-funded warrants to
   purchase common stock

 

 

2,712,478

 

 

 

 

 

 

2,613,482

 

 

 

 

Weighted average shares of common stock
   outstanding used to compute basic and diluted
   net loss per share

 

 

41,443,317

 

 

 

20,059,641

 

 

 

40,182,303

 

 

 

19,767,174

 

Net loss per share, basic and diluted

 

$

(0.79

)

 

$

(1.05

)

 

$

(2.04

)

 

$

(3.83

)

Included within weighted average shares of common stock outstanding for the three and nine months ended September 30, 2024 are 2,712,478 shares of common stock issuable upon the exercise of the pre-funded warrants as the pre-funded warrants are exercisable at any time for nominal consideration, and as such, the shares are considered outstanding for the purpose of calculating basic and diluted net loss per share. There were no pre-funded warrants issued and outstanding during the three and nine months ended September 30, 2023.

Schedule of Antidilutive Securities Excluded from Calculation of Net Loss per Share

The outstanding securities presented below were excluded from the calculation of net loss per share because the inclusion of such securities would have been anti-dilutive due to the Company’s net loss per share during the periods presented.

 

 

 

Three and Nine Months Ended
September 30,

 

 

 

2024

 

 

2023

 

Options to purchase common stock

 

 

2,941,043

 

 

 

2,189,102

 

Nonvested restricted stock units

 

 

1,519,192

 

 

 

946,182

 

Nonvested performance stock units

 

 

2,165,325

 

 

 

 

Shares subject to employee stock purchase plan

 

 

244,302

 

 

 

 

Warrants

 

 

9,230

 

 

 

 

Total

 

 

6,879,092

 

 

 

3,135,284